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1005A-219 Bivalirudin Reduces Hemorrhagic Complications and 
Glycoprotein IlBllllA Inhibitor Usage in Coronary 
Intervention: Results From the NYU Bivalirudin Registry 
Country (Province) 1990 1991 1992 1993 1994 1995 1996 1997 1998 
Michael J. Attubato, Lindsay Friedman, Andrew P. Zinn, Ivan R. Pena-Sing, Robert J. 
Canada (Alberta) 0.5 0.9 1.5 2.1 2.3 3.3 4.9 6.0 8.6 Schanzer, Anthony J. Messina. Stephen Mezzafonte, Howard E. Wirier, Frederick Feit, 
Canada (Ontario) NA NA 0.4 0.6 0.7 0.5 0.7 0.9 1.1 
Canada (Quebec) 0.4 0.5 0.9 1.0 1.4 2.1 2.5 3.3 4.1 
Denmark 0 0 0.1 0.1 0.2 0.6 1.2 1.8 3.4 
England 0.1 0.1 NA NA 0.1 1.3 0.4 0.3 0.3 
Sweden 0.1 0.2 0.3 1 .o 1.4 2.8 4.0 4.5 NA 
U.S. NA 5.2 6.1 7.4 9.0 10.4 11.6 NA NA 
NA=Data not available 
1005A-217 Primary Use of the Cutting Balloon Results in Fewer 
Major Adverse Cardiovascular Events at Six Months 
Than Balloon Angioplasty in a Subgroup of Patients 
With OstiallBifurcation or Small Vessel Lesions 
Tami L. Bair, Joseph B. Muhlestein. Benjamin D. Home, Robert R. Pearson, Clunyu LI, 
Jeffrey L. Anderson, Donald L. LappB. LDS Hospital, Salt Lake City, UT, University of 
Utah, Salt Lake City, UT 
Background: The Cutting Balloon (CB) (Interventional Technologies lnc) incorporates 3 
lo 4 microsurgical blades that produce sharp incisions during dilation, reduclng tearing 
injuries lo the lumen of the target vessel. In randomized trials of type A and B lesions, 
acute and long-term outcomes of CB have not been superior to plain old balloon angio- 
plasty (POBA). However, whether the use of CB can produce results superior to POBA in 
more complicated cases such as ostialibifurcation lesions or in small vessels with post- 
procedure (PP) diameters2.5 mm, remains to be seen. 
Methods: From 1996-2002, in a single institution, 1,580 consecutive patients underwent 
percutaneous coronary intervention for ostialibifurcation lesions or lesions in small ves- 
sels. POBA was utilized as initial therapy in 1,502 and CB in 78 cases. Baseline clinical, 
angiographic. and procedural data were collected and all patients were followed to six 
months for incidence of target vessel revascularization (TVR) and major adverse cardio- 
vascular events (MACE) including death, myocardial infarction and TVR. 
Results: Over-all patient characteristics, including age = 64*12 years, male = 68%. dia- 
betes = 19%. presentation with acute coronary syndrome = 60% did not differ between 
patients receiving POBA or CB. PP vessel diameter was 2.4ti.4 mm for POBA and 
2.720.6 mm for CB (p.zO.001). Adjunctive use of stents was 35% in the POBA group and 
28% in the CB group (p=O.19, OR=O.72). No perforations occurred in either group. TVR 
occurred in 8.1% of POBA and 3.9% of CB (p=O.2O,OR=0.46). MACE occurred in 18.6% 
of POBA and 7.7% of CB (p=O.OO7,OR=0.37). 
Conclusion: Although previous clinical trials involving straightforward type A and B 
lesions have not demonstrated clinical superiority of CB over POBA, in this study of 
select subgroups with ostiaVbifurcation lesions or small vessels, use of CB was associ- 
ated with a significantly lower MACE rate and a clinical trend towards reduced NR. A 
cllnical trend towards reduction in the use of adjundive stenting was also noted with the 
use of CB. 
New York University School of Medicine, New York, NY 
Background: The majority of pts undergoing percutaneous coronary intervention (PCI) 
in the US receive heparin and a GP Ilb/llla inhibitor. In large-scale clinical tnals, the hem- 
orrhagic complication rate (TIMI major + minor hemorrhage) with this regimen has been 
3.5%. We assessed the hypothesis that replacing heparin with bivalirudin would result in 
a low incidence of hemorrhagic and ischemic complications and reduced usage of GP 
Ilb/llla inhibitors. Methods: In 307 pts undergoing PCI, bivalirudin was given as a 0.75 
mg/kg bolus and a 1.75 mglkg infusion during the procedure. Pretreatment with clopi- 
dogrel was encouraged. Two post-PC1 CK-MB measurements were analyzed in all pts 
except those with acute myocardial infarction. Results: The mean age of the pts was 
65?;12 yrs. Multivessel PCI was done in 13%; 1.3 IesionsIpt were treated. Stents were 
implanted in 81% of lewns and 10% of the interventions were in saphenous vein grafts. 
The mean maximum procedural ACT was 38190 sets. Femoral artery closure devices 
were used in 221 (72%) pts. In-hospital events are shown in the table. Conclusion: In 
our single center registry, the substitution of bivalirudin for heparin resulted in a low rate 
of adverse events and low GP Ilb/llia usage. Hemorrhagic complications were decreased 
compared to event rates from previously published trials in pts receiving heparin alone or 
heparin in combination with a GPllb/llla inhibitor. The regimen of bivalirudin and pre-PC1 
clopidogrel therapy IS being tested in the REPLACE-2 Trial. 
In-Hospital Results (n=307) 
n w 
TIMI Major Hemorrhage 0 
TIMI Minor Hemorrhage 2 (0.6) 
Blood Transfusion 0 
Retroperitoneal Bld, Pseudoaneurysm 0 
Death 1 (0.3) 
Q-wave MI 1 (0.3) 
NR - UrgenVAny 1 (0.3) / 3 (0.9) 
MACE 4 (1.2) 
CK-MB > 3x Normal (n=278) 28 (10.0) 
GP llbillla Usage 31 (10.0) 
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Alice Ohanessian, Christophe Caussin, Bernard Lancelin, Pascal Piquet, Sylvie Doubine, 
Hbpital Marie-Lannelongue, Le Plessis Robinson, France 
Background - Recent reports have advocated the use of very low dose unfractionated 
heparin (UFH) (2500 to 5000 IU) among patients undergoing percutaneous coronary 
intervention (PCI). The optimal activated clotting time (ACT) arbitrary recommended for 
PCI is between 300 and 350 s, rarely attalned with low doses of UFH. The purpose of this 
study was to evaluate anticoagulation ranges for low-dose UFH regimens during PCI, 
monitoring APTT. anti-Xa activity and ACT. 
Methods- We prospectively included 250 patients who underwent an ad hoc PCI receiv- 
ing 3000 (n=185) or 4000 (n=65) UFH units. Patients pre-treated by UFH or low weight 
molecular heparin were excluded from the study. At the end of the procedure, ACT 
(Hemochron 401, ITC), APTT and anti-Xa activity (Behring Coagulation Timer) ware 
assayed for each patient arterial blood sample. A good anticoagulation level was defined 
by an anti-Xa activity > 0.4 IUlml and APTT ratio x.5. Creatine kinase (CK) was system- 
atically assayed 8 to 12 hours after PCI (N<150 U/I). periprocedural Ml was defined by 
CK>450. A clinical evaluation was performed at 7 and 30 days. 
Results - age was 63.1 *I 3 years. Weight:76.7+11.7 Kg. Current smokers: 31%, diabe- 
tes: 20%, hypertension: 49.7%, dyslipidemia: 66%. Prior PCI: 48%, prior CABG: 11.5%, 
prior Ml: 34%. Acute coronary syndrome: 65%. Mean heparin dose: 3274 * 459 IU. ACC/ 
AHA classification: A:19.5%, B1:35.9%, B2:32.3%, C: 12.3%. Stenting: 84%, primary 
stenting: 76%. Biological results: ACT: 187i36 s. anti-Xa 0.77eO.3 IU/ml, APTT>120s: 
94%. CK:61t59U/l. Rate of complications: false aneurysm:l%, minor groin 
hematoma:3%. urgent revascularisation:l patient, Ml 0%. death 0%. No MACE at 7 and 
30 days. 
Conclusion - PCI with very low dose UFH (3000 to 4000 IU) appeared to be safe. Anti- 
Xa activity was within therapeutical ranges and APT ratio was > in 94% of the cases 
despite low mean ACT of 187. These findings may explain the safety of PCI with low 
dose heparin. 
1006-l 78 Three-Dimensional Intravascular Ultrasound 
Assessment After the Implantation of Estrogen-Eluting 
PC-Coated Stents in Human Coronary Arteries 
Marco A. Costa, Jose Eduardo M. Sousa, Alexandre A. Abizaid, Andrea S. Abizaid. 
Rodolfo Staico, Luiz A. Mattes, Fausto Feres, lbraim Pinto, Theodore A. Bass, Amanda 
Sousa, EASTER Study Group, University of Florida, Jacksonville, FL, Institute Dante 
Pauanese of Cardiology, Sao Paula, Brazil 
Background Side-effects of anti-proliferative drugs pose limitations lo drug-eluting 
stents. Estrogen inhibited proliferation of smooth muscle cells in animals. Estrogen also 
accelerated endothelial cell growth. We used SD-intravascular ultrasound (IVUS) lo 
determine the human vascular response following the implantation of PC coated stents 
loaded with la-estradiol. 
Methods Thirty patients with de novo coronary disease were treated with the implanta- 
tion of a single 17P-estradiol eluting stent. Clopidogrel was discontinued 28 days post 
stent implantation. IVUS were obtained using a motorized pullback device post-proce- 
dure and at 6 months. Image reconstruction and volumetric analyses were performed by 
an independent core laboratory et the University of Florida, Jacksonville. Measurements 
were performed for the stent and edges segments (5mm proximal and distal). Presence 
of stent malapposition and echolucent intimal tissue (black hole) were determined. 
Results All vessels were patent at 6 months. One patient had repeat revascularization. 
There were no thrombus or black hole images detected by IVUS. There were no late 
Sti?nt malapposition or aneurysm. Percent intimal hyperplasia was only 23.4+-11.9% of 
the stent volume. 
Conclusion This first human experience demonstrates the potential of 17bestradiol 
eluting stems lo prevent neointimal proliferation, without the associated risk of stem 
thrombosis or pathological vascular response. 
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6.Month Volumetric 3D-IVUS Data 
Vl?SSd stent 
(mm? (mm? 
stent 266.5+- t47.7+- 
66.5 43.6 
Proximal 93+-27.3 
Edge 
Distal 76.5+-28 
Edge 
Lumen lntimal Plaque Length 
(mhr? Hyperplasia(mhi’) (mma) (mm) 
115+- 32.6+-14.7 15.1+- 
41.9 1.8 
55+-23.8 37.9+-13 5.01+- 
0.13 
42.7+- 34.2+-12 4.86+- 
22.46 0.4 
1006-179 Elution of Everolimus and Sirolimus From a 
Biodearadable Polvmer Coated Stent Inhibits 
Neointimal Hyperplasia Without Inflammation or 
Toxicity 
Saibal Kar Taku Honda, Dougal Mcclean, Kanama Takizawa, Michael Fishbein, -I 
Hidehiko Honda, John Shulza, Neal Eigler, Frank Litvack, Cedars-Sinai Medical Center, 
Los Angeles, CA, UCLA Medical Center, Los Angeles, CA 
Background: Earfy clinical trials with drug eluting stents have suggested limitations 
including edge restenosis and malaposition. Persistent bio-stable polymer and/or drug 
may be causal. Biodegradable polymers hold potential advantage if they are metabolized 
prior to tissue toxicity and deliver drug during the optimal window. Local delivery of active 
drug from a slowly biodegradable, high molecular weight polylactic acid (PLA) coated 
stent could lead to inhibition of intimal hyperplasia without impaired healing. 
Methods: We compared PLA polymer containing 160 or 220 ug of Everolimus(E), 180 ug 
Sirolimus(S), and bare metal stent. 40 stents were deployed in coronary artehes of 19 
pigs with sacrifice at 28 days. Endpoints were assessed by quantitative coronary angiog 
raphy @CA), histomorphometry, and histology at 28 and 90 days. 
Results:There was reduction of intimal hyperplasia as assessed by QCA and histomor- 
phometry by both E and S (Table 1). At both 28 and 90 days, there was complete re- 
endothelialization and ho difference in inflammation or fibrin between the bare stent and 
druglpolymer groups. 
Conclusion: Everolimus and Sirolimus delivered via stent and thin layer biodegradable 
polymer are equally effective at inhibition of intimal hyperplasia. At follow-up evaluation. 
complete healing without toxic or inflammatory reaction was seen. A clinical trial to deter- 
mine safety and efficacy of the Everolimus coated stent has commenced. 
Table 1. QCA and Histomorphometric parameters at 28 days 
Bare(S) Low E(17) High(E) S(5) 
Late Loss Index 
Area Stenosis% 
lntimal Area 
Injury Score 
0.44*0.20 0.28*0.14 0.29*0.10T 0.3kO.12 
64+24t 4lil2 38ill$ 33*13t 
5.2*1.7 2.8+0.6$ 3.0*1 .o* 2.4*1 .O$ 
1.5*0.9 1.550.5 t .5*0.5 1.6iO.5 
$ p < 0.001 T pco.01 
1006-l 80 Reducing Neointimal Proliferation by a Stent-Based 
Delivery of Nitric Oxide in a Porcine Carotid Overstretch 
Injury Model 
Donamina Hou Hugh Narciso, Kirti Kamdar, Yiyu Zhao. William R. Henog, Bruce 
Barclay, Keith L. March, ICVBM, Indianapolis, IN, Vascular Architects, Inc, San Jose, CA 
Background: Nitric oxide (NO) is a potent vasodilator and anti-platelet agent that sup- 
presses vascular smooth muscle cell proliferation. We hypothesized that releasing NO 
from a stent would reduce neointimal hyperplasia after vascular intervention without 
affecting systemic hemodynamics. The present study was designed to test the efficacy of 
ah NO eluting stent in a porcine carotid overstretch injury model. 
Methods and Results: ePTFE-covered stents (aSpireS Vascular Architects, Inc) with 
the NO-releasing compound sodium nitroprusside (SNP. NO donor)/silicone mixture con- 
taining 54.5 pg SNP were tested. In Virro measurable levels of NO were detected and 
released for 87 days in a conttnuous flow closed-loop PVC tubing system containing PBS 
with a flow rate of 1OOmllmin at room temperature. Six SNPIsilicone mixture coated 
ePTFE-covered stents and six uncoated aspire stents (without SNPlsilicone mixture) 
were implanted in the carotid arteries of 6 pigs following balloon overstretch injury with a 
balloon artery ratio of 1.3:l. Pigs were terminated at 28 days and the vessels were har- 
vested. Quantitative angiography analysis documented ho differences between the base- 
tine vessel parameters. At sacrifice, stents coated with NO significantly decreased 
angiographic lumen narrowing from 37% (control) to 28% (NO eluting, p = 0.022). No 
drug toxicity was observed. Morphometric measurements indicated that the injury score 
was equivalent between groups. The mean intimal thickness was significantly lass in NO 
eluting stent vessels than controls (0.12+0.05 mm vs. 0.43iO.09 mm; P = 0.008). The 
mean neointimal area was also markedly reduced (0.49&0.16 mmz) for arteries receiving 
NO eluting stents compared with the controls (2.40*0.39 mm* , P = 0.00983). Factor VIII 
staining demonstrated complete vessel reendothelialization in most segments of vessel 
of both groups. Conclusions: ePTFE-covered aspire stent-based sustained delivery of 
NO donor via SNPlsilicone mixture is feasible and effectively reduces in-stent neointimal 
hyperplasia at 28 days in a porcine carotid overstretch model. Long-term follow-up is 
needed to determine the persistence of this effect oh neointimal suppression. 
1006-181 Stents Coated With the Lipophilic Compound A24 
Profoundly Inhibit Neointimal Formation in the Porcine 
Coronary Model 
Andrew J. Carter, Lisa Welch, Lori Gibson, Souad Sedlik, Renu Virmani, Providence 
Heart Institute, Portland, OR, Armed Forces Institute of Pathology, Washington, DC 
Background: Stent-based immunosuppressive therapy reduces restenosis by impairing 
vascular smooth muscle cell proliferation and mitigating the inflammatory response to the 
prosthesis. 
Methods: We evaluated the feasibility and efficacy of A24 eluting stems in a porcine cor- 
onary model. Stainless steel balloon expandable stents were coated with a non-erodable 
pOlym.3 or pOlymi?r with A24 (10 w/mm). Fifteen pigs underwent placement of oversized 
bare metal (n = 15) polymer (n = 8) and A24 (n = 9) stents in the coronary arteries. 
Results: At 28-days. histology demonstrated similar mean injury scores for the control, 
polymer and A24 coated stents. The mean neointimal area (mm*) was significantly 
reduced for A24 (1.70 f 0.47) as compared with polymer (2.82 f 1.24) and control (2.89 
f 1.91) stents (p c 0.005). The 40% reduction in neointimal area resulted in significantly 
less mean percent diameter stenosis for A24 (19.4 f 4.0 %) as compared with polymer 
(30.3 * 12.1 %), and control (29.4 * 15.5 %) stents (p < 0.001). Twelve of the 45 bare 
metal stent cross sections exhibited a giant cell reaction while none of the 26 sections 
from the A24 stems had a giant cell response. 
Concfusions: Stent-based delivery of A24 inhibits neointimal formation and the inflam- 
matory response to the prosthesis in the porcine coronary model. Further study IS neces- 
sary to determine the dose-response and long-term effects A24 eluting stents in the 
porcine coronary model. 
1006-l 82 First-in-Human Study of Angiopeptin-Eluting Stents: A 
Quantitative Coronary Angiography and Volumetric 
Intravascular Ultrasound Study 
On-Hina Kwok Wing-Hing Chow, Chi-Hang Lee, William Ng. Tin-Chu Law, Alex Chiu, 
Jeffrey J. Popma. Grantham Hospital, Hong Kong, Hong Kong, Brigham and Women’s 
Hospital, Boston. MA 
Background: Angiopeptin. a somatostatin analogue, has been shown to reduce neointi- 
mal hyperplasia after stenting in various animal models. Angiopeptin inhibits smooth 
muscla cell proliferation through attenuating the production and release of several growth 
factors including PDGF. b-FGF, IGF-1 and EGF. BiodivYsio DD Phosphorylcholine (PC) 
coated stent provides a viable platform for local delivery of anti-proliferative agents to the 
coronary artery. Oblective: To evaluate the feasibility, safety and impact oh tissue growth 
of Angiopeptin-eluting BiodivYsio DD PC stems in human native de nova coronary 
lesions. Method: 13 patients (14 lesions) underwent intravascular ultrasound(lVUS)- 
guided Angiopeptin-eluting stents implantation. The mean age was 83.7+8.7 yrs. 46.2% 
of the patients were diabetic. The clinical follow up period was 28.9+6.8 weeks. Coronary 
arteries between 3.0 and 4.0mm in diameter and lesion lengthcl8mm were included. 
Results: Lesion locations were 9 LAD, 3 LCx and 2 RCA. 13 stents were loaded with 22 
microgram of Angiopeptin and one with 126 microgram. No major adverse cardiac 
events had occurred. Off-line quantitative coronary analysis(QCA) showed pre-proce- 
dural mean reference diameter of 3.23r0.72mm. Minimal luminal diameter(MLD) 
improved from 0.69*0.29mm to 3.19+0.60mm. Mean lesion length,was 12.38~2.04mm. 
8 consecutive patients (9 stents with 22 microgram Angiopeptin) underwent 6-month 
angiographic and volumetric IVUS follow-up. Late loss was 0.55i0.36mm and late loss 
index was 0.23*0.13 by QCA. Binary restenosis was 0%. Follow-up stent volume by 
IVUS was 199.6~123.lmmJ and percentage neointimal hyperplasia volume was 
20.7+28.5%. There was ho edge effect and late stent mal-apposition. Conclusion: Angio- 
peptin-eluting BiodivYsio DD PC stent appears to be feasible and safe in treating native 
de nova coronary lesions. Low-dose (22 microgram) Angiopeptin-eluting stents resulted 
in modest degree of neointimal hyperplasia and zero binary restenosis. More patients will 
be enrolled in the trial with escalating doses of Angiopeptin and the encouraging prelimi- 
nary results warrant further confirmation by randomized controlled trial. 
1006-l 83 First Human Experience Using a New Everolimus Stent 
Coating: Procedural and Six-Month Follow-Up Results 
of the FUTURE Trial 
Eberhard Grube, Lutz Buellesfeld, Ralf Mueller, Manfred Staberock. Guide Selbach. 
Thomas Schmidt, Ulrich Gerckens, Heart Center Siegburg, Siegburg, Germany 
Background: Sirolimus and Paclitaxel eluting stents have shown significant reduction of 
restenosis after stent implantation with remarkable improvement of patient outcome. 
Everolimus is a new anti-proliferative agent binding to cytosolic immunophyllin FKBP12 
and inhibiting arowth factor-driven cell oroliferation with oromisina results in animal stud- _- _ 
ies demonstrating a 50% reduction of neointimal proliferation compared with a bare 
metal stem. The FUTURE trial has been conducted to evaluate both safetv and efficacv 
of the new ChallengeStent, which is coated by a bio-erodable polymer carrying the 
agent Everolimus. 
Methods: The FUTURE trial, which has started in May 2002, is a prospective, random- 
ized, single blinded study including a clinical follow-up at 30 days and 12 months post 
procedure and a 6 month angiographic and IVUS follow-up, to evaluate acute gain and 
late lumen loss due to neointimal proliferation. The primary endpoint is MACE at 30-days. 
The secondary endpoint is to compare the clinical performance of the Everotimus coated 
stent (Challenge-Stem) as compared to the control bare metal S-Stent with regards to 
device success, MACE and restenosis rate at 6.months follow-up. In this randomized 
unbalanced 2:1 ratio, 24 and 12 patients are allocated to the drug and control groups 
respectively. De hove coronary lesions with a reference diameter between 2.75-4.0mm 
and lesion length cl8mm were enrolled with mandatory predilatation. 
Results: To date, the patient enrollment has been completed including 36 patients with a 
procedural success rate of 100%. No in-hospital MACE were reported. At 30.day clinical 
